Evidence map›Paper›PMID 34595432›Full record

ArticleClinical hematology international2019

Induction Therapy with Novel Agents and Autologous Stem Cell Transplant Overcomes the Adverse Impact of Renal Impairment in Multiple Myeloma.

Lalit Kumar, Santosh Kumar Chellapuram, Ramavat Dev, Ankur Varshneya, Satyajit Pawar, Aparna Sharma, Anjali Mookerjee, Ranjit Kumar Sahoo, Prabhat Singh Malik, Atul Sharma and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical hematology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Lalit KumarDepartment of Medical Oncology, Institute Rotary Cancer Hospital, Room 234, IRCH Building, All India Institute of Medical sciences, New Delhi 110029, India.
Santosh Kumar ChellapuramDepartment of Medical Oncology, Institute Rotary Cancer Hospital, Room 234, IRCH Building, All India Institute of Medical sciences, New Delhi 110029, India.
Ramavat DevDepartment of Medical Oncology, Institute Rotary Cancer Hospital, Room 234, IRCH Building, All India Institute of Medical sciences, New Delhi 110029, India.
Ankur VarshneyaDepartment of Medical Oncology, Institute Rotary Cancer Hospital, Room 234, IRCH Building, All India Institute of Medical sciences, New Delhi 110029, India.
Satyajit PawarDepartment of Medical Oncology, Institute Rotary Cancer Hospital, Room 234, IRCH Building, All India Institute of Medical sciences, New Delhi 110029, India.
Aparna SharmaDepartment of Medical Oncology, Institute Rotary Cancer Hospital, Room 234, IRCH Building, All India Institute of Medical sciences, New Delhi 110029, India.
Anjali MookerjeeDepartment of Medical Oncology, Institute Rotary Cancer Hospital, Room 234, IRCH Building, All India Institute of Medical sciences, New Delhi 110029, India.
Ranjit Kumar SahooDepartment of Medical Oncology, Institute Rotary Cancer Hospital, Room 234, IRCH Building, All India Institute of Medical sciences, New Delhi 110029, India.
Prabhat Singh MalikDepartment of Medical Oncology, Institute Rotary Cancer Hospital, Room 234, IRCH Building, All India Institute of Medical sciences, New Delhi 110029, India.
Atul SharmaDepartment of Medical Oncology, Institute Rotary Cancer Hospital, Room 234, IRCH Building, All India Institute of Medical sciences, New Delhi 110029, India.
Ritu GuptaDepartment of Lab Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical sciences, New Delhi 110029, India.
Omdutta SharmaDepartment of Lab Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical sciences, New Delhi 110029, India.
Ahitagni BiswasDepartment of Radiation Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical sciences, New Delhi 110029, India.
Rakesh KumarDepartment of Nuclear Medicine, Institute Rotary Cancer Hospital, All India Institute of Medical sciences, New Delhi 110029, India.
Sanjay ThulkarDepartment of Radiodiagnosis, Institute Rotary Cancer Hospital, All India Institute of Medical sciences, New Delhi 110029, India.
Sauumyaranjan MallickDepartment of Pathology, Institute Rotary Cancer Hospital, All India Institute of Medical sciences, New Delhi 110029, India.
DR. B.R.A. Institute Rotary Cancer Hospital · INAll India Institute of Medical Sciences Bhopal · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the impact of renal impairment (RI) on the outcome in multiple myeloma (MM) patients following induction and autologous stem cell transplantation (ASCT). Among 349 patients who received a first ASCT for MM, 86 (24.6%) had RI at diagnosis, defined as estimation of glomerular filtration rate (eGFR) <40 mL/min/1.73 m

Indexed as

Autologous stem cell transplantationMultiple myelomaReal world experienceRenal impairmentSurvival

Identifiers

PMID34595432
PMCPMC8432369
OpenAlexW2970801600

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.